Outcomes Following the First 100 Cases of a New Robotic Mitral Valve Program

This retrospective analysis evaluated the initiation of a robotic mitral valve surgery program, aiming to delineate surgical outcomes and learning curve trends across a single surgeon’s first 100 consecutive cases (2022–2025). The cohort progressively included complex mitral pathologies and reoperative cardiac patients (10 percent). Outcomes demonstrated an exceptional 99 percent repair rate, with zero 30-day mortality, no postoperative strokes, and an average intensive care unit stay of 1.3-days. The authors discuss that while initial case selection should be conservative, a deliberate expansion to include complex and redo cases—facilitated by endoaortic balloon occlusion—is vital for scaling volume and advancing programmatic proficiency. In this series, the authors report that expansion did not compromise safety, as aortic occlusion times significantly decreased across quartiles. In summary, low morbidity and high repair success rates are attainable early in a robotic program’s inception, even among patients with previous cardiac surgery, complex mitral valve pathology, and severe chest wall deformities.